Renalytix Plc
RENXF
$0.091
-$0.039-30.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.35M | 2.29M | 2.22M | 2.41M | 2.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.35M | 2.29M | 2.22M | 2.41M | 2.89M |
| Cost of Revenue | 2.05M | 2.13M | 2.26M | 2.26M | 2.49M |
| Gross Profit | 299.00K | 156.00K | -35.00K | 152.00K | 404.00K |
| SG&A Expenses | 17.06M | 19.84M | 21.70M | 24.96M | 26.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.44M | 31.17M | 35.52M | 40.49M | 42.29M |
| Operating Income | -24.09M | -28.89M | -33.29M | -38.08M | -39.40M |
| Income Before Tax | -28.02M | -33.45M | -37.48M | -41.84M | -43.81M |
| Income Tax Expenses | 6.00K | 4.00K | 8.00K | 7.00K | 3.00K |
| Earnings from Continuing Operations | -28.03 | -33.46 | -37.49 | -41.85 | -43.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.03M | -33.46M | -37.49M | -41.85M | -43.81M |
| EBIT | -24.09M | -28.89M | -33.29M | -38.08M | -39.40M |
| EBITDA | -23.79M | -28.52M | -32.97M | -37.69M | -38.95M |
| EPS Basic | -0.26 | -0.32 | -0.39 | -0.45 | -0.51 |
| Normalized Basic EPS | -0.14 | -0.17 | -0.21 | -0.26 | -0.28 |
| EPS Diluted | -0.27 | -0.33 | -0.40 | -0.46 | -0.51 |
| Normalized Diluted EPS | -0.14 | -0.17 | -0.21 | -0.26 | -0.28 |
| Average Basic Shares Outstanding | 438.78M | 427.85M | 383.43M | 371.34M | 348.96M |
| Average Diluted Shares Outstanding | 438.78M | 427.85M | 383.43M | 371.34M | 348.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
